Antihypertensive treatment and risk of cardiovascular mortality in patients with chronic kidney disease diagnosed based on the presence of proteinuria and renal function: A large longitudinal study in Japan

Autoři: Kei Nagai aff001;  Kunihiro Yamagata aff001;  Kunitoshi Iseki aff002;  Toshiki Moriyama aff002;  Kazuhiko Tsuruya aff002;  Shouichi Fujimoto aff002;  Ichiei Narita aff002;  Tsuneo Konta aff002;  Masahide Kondo aff001;  Masato Kasahara aff002;  Yugo Shibagaki aff002;  Koichi Asahi aff002;  Tsuyoshi Watanabe aff002
Působiště autorů: University of Tsukuba, Tsukuba, Ibaraki, Japan aff001;  The Steering Committee for “Design of the Comprehensive Health Care System for Chronic Kidney Disease (CKD) Based on the Individual Risk Assessment by Specific Health Checkups”, Tsukuba, Ibaraki, Japan aff002;  Okinawa Heart and Renal Association, Okinawa, Japan aff003;  Health Care Center, Osaka University, Suita, Japan aff004;  Nara Medical University, Nara, Japan aff005;  University of Miyazaki, Miyazaki, Japan aff006;  Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan aff007;  Yamagata University Graduate School of Medical Science, Yamagata, Japan aff008;  Institute for Clinical and Translational Science, Nara Medical University Hospital, Nara, Japan aff009;  St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan aff010;  Iwate Medical University, Morioka, Japan aff011;  Fukushima Rosai Hospital, Iwaki, Japan aff012
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
prolekare.web.journal.doi_sk: 10.1371/journal.pone.0225812


Several recent clinical trials and meta-analyses have shown that lowering blood pressure reduces the risk of cardiovascular disease. However, current evidence that describes general demographics in blood pressure and mortality with chronic kidney disease is sparse in Japan. Using a population-based longitudinal cohort that received annual health checkups in Japan in 2008, hypertensive status, self-reported use of antihypertensive drugs, and prognosis were examined through 2012. Chronic kidney disease was defined as positive proteinuria or estimated glomerular filtration rate <60 ml/min/1.73 m2. Subjects were 40 to 74 years old (n = 227,204) with median 3.6 years follow-up period, and patients with and without chronic kidney disease were analyzed separately (n = 183,586 and n = 43,618, respectively). Cardiovascular disease mortality, comprising coronary heart diseases and stroke as entered in the national death registry using ICD-10 coding, was examined. Among all subjects, 346 deaths (96 in chronic kidney disease and 250 in non-chronic kidney disease) due to cardiovascular disease occurred. Compared with cardiovascular disease mortality in chronic kidney disease patients with untreated normal blood pressure, the multivariable adjusted hazard ratio was 3.08 (95% confidence interval: 1.75–5.41) for those with untreated hypertension, 2.30 (1.31–4.03) for those who became normotensive after treatment, and 3.28 (1.91–5.64) for those who remained hypertensive despite treatment. In non-chronic kidney disease subjects, the ratios were 1.90 (1.33–5.41), 1.95 (1.35–2.80), and 1.77 (1.18–2.66), respectively. These results from a nationwide cohort could be one of representative demographics of controlling blood pressure and cardiovascular disease deaths when treating patients with chronic kidney disease in Japan in recent years. Even after development and spread of anti-hypertensive drugs, preventing development of hypertension is preferable, because any hypertension treatment status comparing untreated normal blood pressure was a risk of cardiovascular mortality at baseline year.

Klíčová slova:

Antihypertensive drugs – Blood pressure – Cardiovascular diseases – Drug therapy – Hypertension – Chronic kidney disease – Proteinuria – Renal system


1. Asayama K, Ohkubo T, Yoshida S, Suzuki K, Metoki H, Harada A, et al. Stroke risk and antihypertensive drug treatment in the general population: the Japan arteriosclerosis longitudinal study. J Hypertens. 2009; 27: 357–364. doi: 10.1097/HJH.0b013e32831967ca 19155790

2. Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. Arch Intern Med. 2003; 163: 361–366. doi: 10.1001/archinte.163.3.361 12578518

3. Ikeda A, Iso H, Yamagishi K, Inoue M, Tsugane S. Blood pressure and the risk of stroke, cardiovascular disease, and all-cause mortality among Japanese: the JPHC Study. Am J Hypertens. 2009; 22: 273–280. doi: 10.1038/ajh.2008.356 19229210

4. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375: 2073–2081. doi: 10.1016/S0140-6736(10)60674-5 20483451

5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2 14656957

6. National Kidney Fundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1–266. 11904577

7. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001; 358: 1305–1315. doi: 10.1016/S0140-6736(01)06411-X 11684211

8. Turnbull F, Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003; 362: 1527–1535. doi: 10.1016/s0140-6736(03)14739-3 14615107

9. Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ. 1998; 317: 167–171. doi: 10.1136/bmj.317.7152.167 9665894

10. Almgren T, Persson B, Wilhelmsen L, Rosengren A, Andersson OK. Stroke and coronary heart disease in treated hypertension—a prospective cohort study over three decades. J Intern Med. 2005; 257: 496–502. doi: 10.1111/j.1365-2796.2005.01497.x 15910553

11. Izumi M, Suzuki K, Sakamoto T, Hayashi M. Advantages and limitations of antihypertensive treatment for stroke risk in a general population: the Akita Stroke Registry. Acta Cardiol. 2011; 66: 729–735. doi: 10.1080/ac.66.6.2136956 22299383

12. Benetos A, Thomas F, Bean KE, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens. 2003; 21: 1635–1640. doi: 10.1097/00004872-200309000-00011 12923394

13. Gudmundsson LS, Johannsson M, Thorgeirsson G, Sigfusson N, Sigvaldason H, Witteman JC. Risk profiles and prognosis of treated and untreated hypertensive men and women in a population-based longitudinal study: the Reykjavik Study. J Hum Hypertens. 2004; 18: 615–622. doi: 10.1038/sj.jhh.1001725 15071487

14. Li C, Engstrom G, Hedblad B, Berglund G, Janzon L. Blood pressure control and risk of stroke: a population-based prospective cohort study. Stroke. 2005; 36: 725–730. doi: 10.1161/01.STR.0000158925.12740.87 15746450

15. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387: 957–967. doi: 10.1016/S0140-6736(15)01225-8 26724178

16. Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359: 2417–2428. doi: 10.1056/NEJMoa0806182 19052124

17. Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008; 51: 393–398. doi: 10.1161/HYPERTENSIONAHA.107.098475 18172059

18. Rakugi H, Ogihara T, Umemoto S, Matsuzaki M, Matsuoka H, Shimada K, et al. Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial. Hypertens Res. 2013; 36: 947–958. doi: 10.1038/hr.2013.63 23864054

19. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290: 2805–2816. doi: 10.1001/jama.290.21.2805 14657064

20. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005; 36: 1218–1226. doi: 10.1161/01.STR.0000166048.35740.a9 15879332

21. Ogihara T. Practitioner's Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens. 2000; 13: 461–467. doi: 10.1016/s0895-7061(99)00215-0 10826395

22. Iseki K, Asahi K, Moriyama T, Yamagata K, Tsuruya K, Yoshida H, et al. Risk factor profiles based on estimated glomerular filtration rate and dipstick proteinuria among participants of the Specific Health Check and Guidance System in Japan 2008. Clin Exp Nephrol. 2012; 16: 244–249. doi: 10.1007/s10157-011-0551-9 22057582

23. Yano Y, Sato Y, Fujimoto S, Konta T, Iseki K, Moriyama T, et al. Association of high pulse pressure with proteinuria in subjects with diabetes, prediabetes, or normal glucose tolerance in a large Japanese general population sample. Diabetes Care. 2012; 35: 1310–1315. doi: 10.2337/dc11-2245 22474041

24. Sato Y, Yano Y, Fujimoto S, Konta T, Iseki K, Moriyama T, et al. Glycohemoglobin not as predictive as fasting glucose as a measure of prediabetes in predicting proteinuria. Nephrol Dial Transplant. 2012; 27: 3862–3868. doi: 10.1093/ndt/gfs324 22859789

25. Nagai K, Yamagata K, Ohkubo R, Saito C, Asahi K, Iseki K, et al. Annual decline in estimated glomerular filtration rate is a risk factor for cardiovascular events independent of proteinuria. Nephrology (Carlton). 2014; 19: 574–580.

26. Iseki K, Asahi K, Yamagata K, Fujimoto S, Tsuruya K, Narita I, et al. (2017) Mortality risk among screened subjects of the specific health check and guidance program in Japan 2008–2012. Clin Exp Nephrol. 2017; 21: 978–985. doi: 10.1007/s10157-017-1392-y 28258498

27. Iseki K, Horio M, Imai E, Matsuo S, Yamagata K. Geographic difference in the prevalence of chronic kidney disease among Japanese screened subjects: Ibaraki versus Okinawa. Clin Exp Nephrol. 2009; 13: 44–49. doi: 10.1007/s10157-008-0080-3 18854923

28. Subcommittee Guidelines. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999; 17: 151–83. 10067786

29. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296–1305. doi: 10.1056/NEJMoa041031 15385656

30. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. 2006; 296: 1255–1265. doi: 10.1001/jama.296.10.1255 16968850

31. Yasui D, Asayama K, Ohkubo T, Kikuya M, Kanno A, Hara A, et al. Stroke risk in treated hypertension based on home blood pressure: the Ohasama study. Am J Hypertens. 2010; 23: 508–514. doi: 10.1038/ajh.2010.15 20186131

32. Nakanishi S, Yamada M, Hattori N, Suzuki G. Relationship between HbA1c and mortality in a Japanese population. Diabetologia. 2005; 48: 230–234. doi: 10.1007/s00125-004-1643-9 15650819

33. Ueshima H, Choudhury SR, Okayama A, Hayakawa T, Kita Y, et al. Cigarette smoking as a risk factor for stroke death in Japan: NIPPON DATA80. Stroke. 2004; 35: 1836–1841. doi: 10.1161/01.STR.0000131747.84423.74 15166389

34. Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshima H, et al. The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis. 2006; 184: 143–150. doi: 10.1016/j.atherosclerosis.2005.03.042 15913635

35. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007; 71: 159–166. doi: 10.1038/ 17136030

36. Blood Pressure Lowering Treatment Trialists C, Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013; 347: f5680. doi: 10.1136/bmj.f5680 24092942

37. Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, et al. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney Int. 2013; 83: 167–176. doi: 10.1038/ki.2012.326 23051740

Článok vyšiel v časopise


2019 Číslo 12